|
Biogen Idec Inc (BIIB) news: Biogen Idec’s CEO Presents at Cowen & Company …
Seeking Alpha We have Daclizumab HYP that we hope that we will get a readout for in a Phase III trial later this year. We have it listed here but we don’t really know how the data will shape up, so take that one with a little bit of a grain of salt. But we hope that … |
Good reception for ReceptosU-T San DiegoMoussatos says Receptos is likely to be an even bigger success for MS than daclizumab, sold as by Roche as Zenapax. An estimated 400,000 people in the United States and 2.5 million people worldwide have multiple …
|
Comparison of Cytomegalovirus (CMV) Enzyme-Linked Immunosorbent Spot …
Journal of Clinical Microbiology The following statement should be inserted at the end of line 9: “The following induction immunosuppressive treatments were employed: antithymocyte globulin (ATG) for 67/120 patients (56%) (median age of cohort, 60 years), basiliximab for 47/120 … |
|
优时比联手百健艾迪在亚洲推广创新药物
汉丰网 根据协议条款，百健艾迪将向优时比公司提供其多发性硬化症药物，包括TECFIDERA、FAMPYRA、AVONEX、TYSABRI、PLEGRIDY和Daclizumab High-Yield Process(DAC HYP)，以及长效基因重组治疗血友病的药物ELOCTATE和ALPROLIX … |
|
Lungentransplantation – Therapieoption bei Lungenerkrankungen im Endstadium
Deutsches Ärzteblatt In den letzten Jahren haben die Einführung der „mammalian target of rapamycin“(mTOR)-Inhibitoren (Sirolimus und Everolimus) und des Anti-CD25-Antikörpers (Daclizumab, Basiliximab – nur Induktionstherapie) die Kombinationsmöglichkeiten erweitert (24, … |
|
Here’s Why Biogen Could Be in Store for a Big 2014
Motley Fool It’s been a great year for Biogen (NASDAQ: BIIB ) investors. Shares in the company have more than doubled as sales climbed more than 25% to nearly $7 billion in the past year. A lot of that success is thanks to surging sales for its new oral MS drug … |
|
Hot Stocks Alert: Biogen Idec Inc (NASDAQ:BIIB), Synta Pharmaceuticals Corp …
Market News Call As part of the relationship, Biogen Idec will supply UCB with its portfolio of multiple sclerosis (MS) therapies and investigational candidates, including TECFIDERA®, FAMPYRA®, AVONEX®, TYSABRI®, PLEGRIDY™ and Daclizumab High-Yield Process … |
AbbVie Inc. (ABBV): New Analyst Report from Zacks Equity Research – Zacks …NASDAQ… (phase III ongoing for triple negative breast cancer), elotuzumab (multiple myeloma phase III studies ongoing with results due in early 2015 partnered with Bristol-M…
|
AbbVie Inc. Is Closer to Much-Needed Diversification, but Is It Enough?
DailyFinance Other drugs like Elagolix and daclizumab also address meaningful potential markets, and AbbVie isn’t known for moving low-probability drugs into expensive late-stage tests. Even so, there are “buts” here – the success of Elagolix and daclizumab will … |
|
AbbVie Inc. Is Closer to Much-Needed Diversification, but Is It Enough?
Motley Fool Other drugs like Elagolix and daclizumab also address meaningful potential markets, and AbbVie isn’t known for moving low-probability drugs into expensive late-stage tests. Even so, there are “buts” here – the success of Elagolix and daclizumab will … |